Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Outcomes of corneal transplantation for advanced keratoconus

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Surgical Cornea

Venue: Poster Village: Pod 2

First Author: : H.Sitnik BELARUS

Co Author(s): :                           

Abstract Details

Purpose:

To evaluate the clinical outcomes after corneal transplantation in patients with advanced keratoconus.

Setting:

Chair of ophthalmology of Belarusian medical academy of post-graduate education

Methods:

The clinical records and results of treatment of keratoconus patients were retrospectively studied. A total number of 255 patients (257 eyes) who underwent PKP or DALK between 2012 to 2018 were included in the study. There were 154 men, 101 women, mean age 34.1 ± 11.5 y.o. Advanced keratoconus was diagnosed in all cases. Corneal scars and opacities were revealed in 38 cases, minimal corneal thickness was 279 ± 98 µm (from 110 µm to 385 µm). PKP was performed on 209 eyes, including 120 femto-assisted and 89 manual keratoplasty. DALK was done in 48 cases, including 24 femto-assisted  operations.

Results:

Postoperative refraction was myopic in most of the cases. UCVA was comparable in DALK and PKP groups: 0.38±0.27 and 0.37±0.22. ECD was higher in DALK patients – 1876±189, 1520±287 in PKP. The myopic increase was observed during 5-year follow up. Keratometry was 47.4±2  in DALK, 48.1±1.9 in PKP patients. High postkeratoplasty astigmatism was revealed in 12.4% in manual technique and 8.3% in femto-assisted. Special sing was observed in DALK group – Descemet membrane folds/scars – when preop corneal thickness was less 270 µm (4 eyes). 2 cases of postop scar ectasia revealed after PKP. Transplant rejection/opacities – 6 eyes.

Conclusions:

Comparable visual acuity outcomes were observed in DALK and PKP groups. The predominant postoperative refraction was myopic. Postkeratoplasty astigmatism was significantly higher in manual technique of keratoplasty.

Financial Disclosure:

None

Back to previous